Your browser doesn't support javascript.
loading
Time to reconsider moxifloxacin anti-anaerobic activity?
Principe, Luigi; Sanson, Gianfranco; Luzzati, Roberto; Aschbacher, Richard; Pagani, Elisabetta; Luzzaro, Francesco; Di Bella, Stefano.
Afiliação
  • Principe L; Clinical Pathology and Microbiology Unit, "San Giovanni di Dio" Hospital, Crotone, Italy.
  • Sanson G; Clinical Department of Medical, Surgical and Health Sciences, Trieste University, Trieste, Italy.
  • Luzzati R; Clinical Department of Medical, Surgical and Health Sciences, Trieste University, Trieste, Italy.
  • Aschbacher R; Microbiology and Virology Laboratory, Health Service of Bolzano, Bolzano, Italy.
  • Pagani E; Microbiology and Virology Laboratory, Health Service of Bolzano, Bolzano, Italy.
  • Luzzaro F; Clinical Microbiology and Virology Unit, "A. Manzoni" Hospital, Lecco, Italy.
  • Di Bella S; Clinical Department of Medical, Surgical and Health Sciences, Trieste University, Trieste, Italy.
J Chemother ; 35(4): 367-368, 2023 Jul.
Article em En | MEDLINE | ID: mdl-35947127
Large data on moxifloxacin activity on anaerobes are old. Moxifloxacin is often used for empiric therapy therefore the knowledge of current epidemiologic data is fundamental. We analyzed 69 anaerobic strains, from a recent multicenter Italian study, for moxifloxacin susceptibility. Using EUCAST criteria 81% of Bacteroides spp. and 48% of anaerobes other than Bacteroides were resistant to moxifloxacin. Using CLSI criteria moxifloxacin resistance rates decrease to 35% for all anaerobes, and to 41% for Bacteroides spp. We reported an alarming increase in moxifloxacin resistance among anaerobes in Italy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bactérias Anaeróbias / Antibacterianos Tipo de estudo: Clinical_trials Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bactérias Anaeróbias / Antibacterianos Tipo de estudo: Clinical_trials Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article